Overview

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Treatments:
Gemcitabine